Movement disorders in paraneoplastic and autoimmune disease

Current Opinion in Neurology

Volumn 24, Issue 4, 2011, Pages 346-353

  Panzer, Jessica ^a   Dalmau, Josep ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

antibodies; ataxia; autoimmune; chorea; dyskinesia; dystonia; encephalitis,immunotherapy; movement disorders; paraneoplastic

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; AMPHIPHYSIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 65; IMMUNOGLOBULIN; RITUXIMAB; VOLTAGE GATED CALCIUM CHANNEL;

ANTIPHOSPHOLIPID SYNDROME; ANXIETY; ARTICLE; ATAXIA; AUTOIMMUNE DISEASE; BREAST CANCER; CEREBELLUM DEGENERATION; CHOREA; CHOREA MINOR; COMPULSION; DISEASE ASSOCIATION; DYSKINESIA; ENCEPHALITIS; ENCEPHALOMYELITIS; GROUP A STREPTOCOCCAL INFECTION; GYNECOLOGICAL EXAMINATION; HUMAN; HYPOKINESIA; IMMUNOTHERAPY; LUNG SMALL CELL CANCER; LYMPHOMA; MOTOR DYSFUNCTION; MUSCLE SPASM; MYOCLONUS; MYOKYMIA; NEUROBLASTOMA; OBSESSION; OPSOCLONUS MYOCLONUS SYNDROME; PARANEOPLASTIC SYNDROME; PARANOIA; PLASMAPHERESIS; RIGIDITY; STIFF MAN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOMA; THYMOMA; TREMOR;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; HUMANS; IMMUNOTHERAPY; MOVEMENT DISORDERS; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM;

EID: 79960837288     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328347b307     Document Type: Article

References (115)

1. Grant R, Graus F. Paraneoplastic movement disorders. Mov Disord 2009; 24:1715-1724.
2. Darnell RB, Posner JB. Paraneoplastic syndromes affecting the nervous system. Semin Oncol 2006; 33:270-298. (Pubitemid 43849931)
3. Psimaras D, Carpentier AF, Rossi C. Cerebrospinal fluid study in paraneoplastic syndromes. J Neurol Neurosurg Psychiatry 2010; 81:42-45.
4. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75:1135-1140. (Pubitemid 39005770)
5. Samii A, Dahlen DD, Spence AM, et al. Paraneoplastic movement disorder in a patient with non-Hodgkin's lymphoma and CRMP-5 autoantibody. Mov Disord 2003; 18:1556-1558. (Pubitemid 38035387)
6. Vernino S, Tuite P, Adler CH, et al. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol 2002; 51:625-630.
7. Yu Z, Kryzer TJ,GriesmannGE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001; 49:146-154. (Pubitemid 32157990)
8. Muehlschlegel S, Okun MS, Foote KD, et al. Paraneoplastic chorea with leukoencephalopathy presenting with obsessive-compulsive and behavioral disorder. Mov Disord 2005; 20:1523-1527. (Pubitemid 43072665)
9. Honnorat J, Cartalat-Carel S, Ricard D, et al. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 2009; 80:412-416.
10. Bonthius DJ, Karacay B. Sydenham's chorea: not gone and not forgotten. Semin Pediatr Neurol 2003; 10:11-19. (Pubitemid 36618334)
11. Zomorrodi A, Wald ER. Sydenham's chorea in western Pennsylvania. Pediatrics 2006; 117:e675-e679. (Pubitemid 46071470)
12. Ridel KR, Lipps TD, Gilbert DL. The prevalence of neuropsychiatric disorders in Sydenham's chorea. Pediatr Neurol 2010; 42:243-248.
13. Cardoso F, Eduardo C, Silva AP, et al. Chorea in fifty consecutive patients with rheumatic fever. Mov Disord 1997; 12:701-703. (Pubitemid 27406264)
14. Faustino PC, Terreri MT, da Rocha AJ, et al. Clinical, laboratory, psychiatric and magnetic resonance findings in patients with Sydenham chorea. Neuroradiology 2003; 45:456-462. (Pubitemid 36944059)
15. Berrios X, Quesney F, Morales A, et al. Are all recurrences of 'pure' Sydenham chorea true recurrences of acute rheumatic fever? J Pediatr 1985; 107:867-872. (Pubitemid 16197092)
16. Church AJ, Dale RC, Cardoso F, et al. CSF and serum immune parameters in Sydenham's chorea: evidence of an autoimmune syndrome? J Neuroimmunol 2003; 136:149-153. (Pubitemid 36300800)
17. Husby G, Li L, Davis LE, Wedege E, et al. Antibodies to human caudate nucleus neurons in Huntington's chorea. J Clin Invest 1977; 59:922-932. (Pubitemid 8096344)
18. Sanchez-Carpintero R, Albesa SA, Crespo N, et al. A preliminary study of the frequency of antibasal ganglia antibodies and streptococcal infection in attention deficit/hyperactivity disorder. J Neurol 2009; 256:1103-1108.
19. Kirvan CA, Cox CJ, Swedo SE, et al. Tubulin is a neuronal target of autoantibodies in Sydenham's chorea. J Immunol 2007; 178:7412-7421. (Pubitemid 46847469)
20. Bronze MS, Dale JB. Epitopes of streptococcal M proteins that evoke antibodies that cross-react with human brain. J Immunol 1993; 151: 2820-2828. (Pubitemid 23264534)
21. Kirvan CA, Swedo SE, Kurahara D, et al. Streptococcal mimicry and antibody-mediated cell signaling in the pathogenesis of Sydenham's chorea. Autoimmunity 2006; 39:21-29. (Pubitemid 43878517)
22. Kirvan CA, Swedo SE, Heuser JS, et al. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med 2003; 9:914-920. (Pubitemid 36889935)
23. American Academy of Pediatrics, Committee on Infectious Diseases. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. American Academy of Pediatrics; 2009.
24. Cardoso F, Vargas AP, Oliveira LD, et al. Persistent Sydenham's chorea. Mov Disord 1999; 14:805-807. (Pubitemid 29509623)
25. Korn-Lubetzki I, Brand A, Steiner I. Recurrence of Sydenham chorea: implications for pathogenesis. Arch Neurol 2004; 61:1261-1264. (Pubitemid 39062681)
26. Garvey MA, Snider LA, Leitman SF, et al. Treatment of Sydenham's chorea with intravenous immunoglobulin, plasma exchange, or prednisone. J Child Neurol 2005; 20:424-429. (Pubitemid 40873048)
27. Daoud AS, Zaki M, Shakir R, et al. Effectiveness of sodium valproate in the treatment of Sydenham's chorea. Neurology 1990; 40:1140-1141. (Pubitemid 20213991)
28. Ronchezel MV, Hilario MO, Forleo LH, et al. The use of haloperidol and valproate in children with Sydenham chorea. Indian Pediatr 1998; 35:1215-1218. (Pubitemid 29018377)
29. Khamashta MA, Bertolaccini ML, Hughes GR. Antiphospholipid (Hughes) syndrome. Autoimmunity 2004; 37:309-312. (Pubitemid 39172918)
30. Khamashta MA, Gil A, Anciones B, et al. Chorea in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis 1988; 47:681-683.
31. Cervera R, Asherson RA, Font J, et al. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore) 1997; 76:203-212. (Pubitemid 27255823)
32. Orzechowski NM, Wolanskyj AP, Ahlskog JE, et al. Antiphospholipid antibody-associated chorea. J Rheumatol 2008; 35:2165-2170.
33. Chapman J, Cohen-Armon M, Shoenfeld Y, et al. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999; 8:127-133. (Pubitemid 29103599)
34. Zandman-Goddard G, Chapman J, Shoenfeld Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum 2007; 36:297-315. (Pubitemid 46517634)
35. Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10:63-74.
36. Johnson N, Henry C, Fessler AJ, et al. Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus. Neurology 2010; 75:1480-1482.
37. Iizuka T, Sakai F, Ide T, et al. Anti-NMDA receptor encephalitis in Japan: longterm outcome without tumor removal. Neurology 2008; 70:504-511. (Pubitemid 351653374)
38. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7:1091-1098.
39. Kleinig TJ, Thompson PD, Matar W, et al. The distinctive movement disorder of ovarian teratoma-associated encephalitis. Mov Disord 2008; 23:1256-1261.
40. Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly nonparaneoplastic disorder of both sexes. Brain 2010; 133:1655-1667.
41. Tonomura Y, Kataoka H, Hara Y, et al. Clinical analysis of paraneoplastic encephalitis associated with ovarian teratoma. J Neurooncol 2007; 84:287-292. (Pubitemid 47108520)
42. Koide R, Shimizu T, Koike K, et al. EFA6A-like antibodies in paraneoplastic encephalitis associated with immature ovarian teratoma: a case report. J Neurooncol 2007; 81:71-74. (Pubitemid 44963992)
43. Bayreuther C, Bourg V, Dellamonica J, et al. Complex partial status epilepticus revealing anti-NMDA receptor encephalitis. Epileptic Disord 2009; 11:261-265.
44. Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010; 30:5866-5875.
45. Eker A, Saka E, Dalmau J, et al. Testicular teratoma and anti-N-methyl-Daspartate receptor-associated encephalitis. J Neurol Neurosurg Psychiatry 2008; 79:1082-1083.
46. Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009; 66:11-18.
47. Dalmau J, Tuzun E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61:25-33.
48. Kirkpatrick MP, Clarke CD, Sonmezturk HH, et al. Rhythmic delta activity represents a form of nonconvulsive status epilepticus in anti-NMDA receptor antibody encephalitis. Epilepsy Behav 2011; 20:392-394.
49. Sansing LH, Tuzun E, Ko MW, et al. A patient with encephalitis associated with NMDA receptor antibodies. Nat Clin Pract Neurol 2007; 3:291-296. (Pubitemid 46745476)
50. Dale RC, Irani SR, Brilot F, et al. N-methyl-D-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol 2009; 66:704-709.
51. Ishiura H, Matsuda S, Higashihara M, et al. Response of anti-NMDA receptor encephalitis without tumor to immunotherapy including rituximab. Neurology 2008; 71:1921-1923.
52. Wong-Kisiel LC, Ji T, Renaud DL, et al. Response to immunotherapy in a 20-month-old boy with anti-NMDA receptor encephalitis. Neurology 2010; 74:1550-1551.
53. Rosenfeld MR, Eichen JG, Wade DF, et al. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 2001; 50:339-348. (Pubitemid 32848736)
54. Bennett JL, Galetta SL, Frohman LP, et al. Neuro-ophthalmologic manifestations of a paraneoplastic syndrome and testicular carcinoma. Neurology 1999; 52:864-867. (Pubitemid 29120201)
55. Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004; 127:1831-1844. (Pubitemid 39061559)
56. Hoffmann LA, Jarius S, Pellkofer HL, et al. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: twenty-two newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatry 2008; 79:767-773. (Pubitemid 351914721)
57. Castle J, Sakonju A, Dalmau J, et al. Anti-Ma2-associated encephalitis with normal FDG-PET: a case of pseudo-Whipple's disease. Nat Clin Pract Neurol 2006; 2:566-572. (Pubitemid 44445812)
58. Mathew RM, Vandenberghe R, Garcia-Merino A, et al. Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis. Neurology 2007; 68:900-905. (Pubitemid 46568501)
59. de Beukelaar JW, Sillevis Smitt PA. Managing paraneoplastic neurological disorders. Oncologist 2006; 11:292-305.
60. Kraker J. Treatment of anti-Ma2/Ta paraneoplastic syndrome. Curr Treat Options Neurol 2009; 11:46-51.
61. Brown P, Marsden CD. The stiff man and stiff man plus syndromes. J Neurol 1999; 246:648-652. (Pubitemid 29417843)
62. Hernandez-Echebarria L, Saiz A, Ares A, et al. Paraneoplastic encephalomyelitis associated with pancreatic tumor and anti-GAD antibodies. Neurology 2006; 66:450-451. (Pubitemid 43739960)
63. Saiz A, Blanco Y, Sabater L, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008; 131:2553-2563.
64. Alexopoulos H, Dalakas MC. A critical update on the immunopathogenesis of Stiff Person syndrome. Eur J Clin Invest 2010; 40:1018-1025.
65. Antoine JC, Absi L, Honnorat J, et al. Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors. Arch Neurol 1999; 56:172-177. (Pubitemid 29076181)
66. Dorresteijn LD, Kappelle AC, Renier WO, et al. Antiamphiphysin associated limbic encephalitis: a paraneoplastic presentation of small-cell lung carcinoma. J Neurol 2002; 249:1307-1308. (Pubitemid 35025113)
67. Ishii A, Hayashi A, Ohkoshi N, et al. Progressive encephalomyelitis with rigidity associated with antiamphiphysin antibodies. J Neurol Neurosurg Psychiatry 2004; 75:661-662. (Pubitemid 38406678)
68. Pittock SJ, Lucchinetti CF, Parisi JE, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 2005; 58:96-107. (Pubitemid 40962465)
69. Murinson BB, Guarnaccia JB. Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology 2008; 71: 1955-1958.
70. Manto MU, Laute MA, Aguera M, et al. Effects of antiglutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol 2007; 61:544-551. (Pubitemid 47068136)
71. Geis C, Weishaupt A, Hallermann S, et al. Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain 2010; 133:3166-3180.
72. Raju R, Rakocevic G, Chen Z, et al. Autoimmunity to GABAA- receptorassociated protein in Stiff-person syndrome. Brain 2006; 129:3270-3276. (Pubitemid 44871441)
73. Mas N, Saiz A, Leite MI, et al. Antiglycine-receptor encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 2010 [Epub ahead of print]. Clinical characterization of three patients with glycine receptor antibodies.
74. Hutchinson M, Waters P, McHugh J, et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology 2008; 71:1291-1292.
75. Dalakas MC, Fujii M, Li M, et al. High-dose intravenous immune globulin for Stiff-person syndrome. N Engl J Med 2001; 345:1870-1876. (Pubitemid 33716561)
76. Vasconcelos OM, Dalakas MC. Stiff-person syndrome. Curr Treat Options Neurol 2003; 5:79-90.
77. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008; 7:327-340. (Pubitemid 351380534)
78. Karmon Y, Inbar E, Cordoba M, et al. Paraneoplastic cerebellar degeneration mimicking acute postinfectious cerebellitis. Cerebellum 2009; 8:441-444.
79. Rojas I, Graus F, Keime-Guibert F, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000; 55:713-715.
80. Bernal F, Shams'ili S, Rojas I, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003; 60:230-234. (Pubitemid 36152014)
81. Graus F, Lang B, Pozo-Rosich P, et al. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 2002; 59:764-766.
82. Demarquay G, Honnorat J. Clinical presentation of immune-mediated cerebellar ataxia. Rev Neurol (Paris) 2010 [Epub ahead of print].
83. Burk K, Wick M, Roth G, et al. Antineuronal antibodies in sporadic late-onset cerebellar ataxia. J Neurol 2010; 257:59-62.
84. Sillevis SP, Kinoshita A, De Leeuw B, et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 2000; 342:21-27. (Pubitemid 30020656)
85. Marignier R, Chenevier F, Rogemond V, et al. Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease? Arch Neurol 2010; 67:627-630.
86. Taniguchi Y, Tanji C, Kawai T, et al. A case report of plasmapheresis in paraneoplastic cerebellar ataxia associated with anti-Tr antibody. Ther Apher Dial 2006; 10:90-93.
87. Keime-Guibert F, Graus F, Fleury A, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000; 68:479-482. (Pubitemid 30248748)
88. Wong A. An update on opsoclonus. Curr Opin Neurol 2007; 20:25-31. (Pubitemid 46090139)
89. Digre KB. Opsoclonus in adults. Report of three cases and review of the literature. Arch Neurol 1986; 43:1165-1175. (Pubitemid 17174446)
90. Luque FA, Furneaux HM, Ferziger R, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991; 29:241-251.
91. Blaes F, Pike MG, Lang B. Autoantibodies in childhood opsoclonus-myoclonus syndrome. J Neuroimmunol 2008; 201:221-226.
92. Kirsten A, Beck S, Fuhlhuber V, et al. New autoantibodies in pediatric opsoclonus myoclonus syndrome. Ann N Y Acad Sci 2007; 1110:256-260. (Pubitemid 350043014)
93. Pranzatelli MR, Travelstead AL, Tate ED, et al. B-and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology 2004; 62:1526-1532. (Pubitemid 38608190)
94. Pranzatelli MR, Tate ED, Travelstead AL, et al. Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonusmyoclonus. J Clin Immunol 2010; 30:106-113.
95. Pranzatelli MR, Tate ED, Swan JA, et al. B cell depletion therapy for newonset opsoclonus-myoclonus. Mov Disord 2010; 25:238-242.
96. Gorman MP. Update on diagnosis, treatment, and prognosis in opsoclonusmyoclonus-ataxia syndrome. Curr Opin Pediatr 2010; 22:745-750.
97. Mitchell WG, Brumm VL, Azen CG, et al. Longitudinal neurodevelopmental evaluation of children with opsoclonus-ataxia. Pediatrics 2005; 116:901-907. (Pubitemid 44542816)
98. Bataller L, Graus F, Saiz A, et al. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001; 124:437-443. (Pubitemid 32142415)
99. Erlich R, Morrison C, Kim B, et al. ANNA-2: an antibody associated with paraneoplastic opsoclonus in a patient with large-cell carcinoma of the lung with neuroendocrine features: correlation of clinical improvement with tumor response. Cancer Invest 2004; 22:257-261. (Pubitemid 38725180)
100. Hart IK, Maddison P, Newsom-Davis J, et al. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain 2002; 125:1887-1895.
101. Liguori R, Vincent A, Clover L, et al. Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 2001; 124:2417-2426. (Pubitemid 33134931)
102. Lahrmann H, Albrecht G, Drlicek M, et al. Acquired neuromyotonia and peripheral neuropathy in a patient with Hodgkin's disease. Muscle Nerve 2001; 24:834-838. (Pubitemid 32476533)
103. Rubio-Agust?́ I, Perez-Miralles F, Sevilla T, et al. Peripheral nerve hyperexcitability: a clinical and immunologic study of 38 patients. Neurology 2011; 76:172-178.
104. Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010; 9:776-785.
105. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channelcomplex proteins leucine-rich, glioma inactivated 1 protein and contactinassociated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010; 133:2734-2748.
106. Vincent A. Antibodies to contactin-associated protein 2 (CASPR2) in thymoma and Morvan's syndrome [abstract]. Ann Neurol 2009; 66 (Suppl 13) S3. First report indicating that Caspr2 antibodies associate with neuromyotonia, Morvan's syndrome, thymoma, and poor response to treatment.
107. Newsom-Davis J, Buckley C, Clover L, et al. Autoimmune disorders of neuronal potassium channels. Ann N Y Acad Sci 2003; 998:202-210. (Pubitemid 37194161)
108. Bernal F, Graus F, Pifarre A, et al. Immunohistochemical analysis of anti-Huassociated paraneoplastic encephalomyelitis. Acta Neuropathol (Berl) 2002; 103:509-515. (Pubitemid 36075348)
109. Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124:1138-1148. (Pubitemid 32510382)
110. Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. Eur J Neurol 2011; 18:19-23.
111. Graus F, Dalmau J. Paraneoplastic neurological syndromes: diagnosis and treatment. Curr Opin Neurol 2007; 20:732-737. (Pubitemid 350085019)
112. Shams'ili S, de Beukelaar J, Gratama JW, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 2006; 253:16-20. (Pubitemid 43157382)
113. Vernino S, O'Neill BP, Marks RS, et al. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro-oncol 2004; 6:55-62. (Pubitemid 38139640)
114. Tuzun E, Dalmau J. Limbic encephalitis and variants: classification, diagnosis and treatment. Neurologist 2007; 13:261-271. (Pubitemid 47396312)
115. Rosenfeld MR, Dalmau J. Update on paraneoplastic and autoimmune disorders of the central nervous system. Semin Neurol 2010; 30:320-331.